Valuation: Pluristem Therapeutics

Market Cap 11.6M 10.36M 9.63M 8.76M 16.47M 1.1B 16.77M 116M 45.24M 573M 43.55M 42.62M 1.83B P/E 2025
-1.39x
P/E 2026 -0.85x
Enterprise Value 38.71M 34.56M 32.12M 29.21M 54.96M 3.67B 55.95M 386M 151M 1.91B 145M 142M 6.12B EV / Sales 2025
39,078,124x
EV / Sales 2026 48,916,935x
Free-Float
57.48%
Yield 2025 *
-
Yield 2026 -
Manager TitleAgeSince
Chief Executive Officer 54 28/03/2017
Director of Finance/CFO 42 30/11/2022
Chief Operating Officer - 31/12/2024
Director TitleAgeSince
Director/Board Member 54 31/01/2015
Director/Board Member 56 05/01/2021
Director/Board Member 64 31/05/2021
Change 5-day change 1-year change 3-year change Capi.($)
+3.38%-1.33% - - 11.6M
+0.21%-4.63%+55.34%+71.32% 68.98B
+0.08%+4.28%+6.81%+61.62% 53.15B
-0.48%+5.35%+9.96%+41.47% 50.83B
+3.45%+4.70%+33.44%+35.96% 44.61B
-2.20%+0.61%+281.88%+532.76% 40.57B
+6.43%+6.84%+18.32%+109.23% 42.53B
+1.28%+1.39%+11.69%+45.10% 30.95B
-0.90%-10.49%+31.48%-1.63% 25.44B
+1.74%-2.02%-13.55%-12.92% 22.66B
Average +1.30%+1.56%+48.37%+98.10% 42.19B
Weighted average by Cap. +1.03%+2.33%+50.69%+103.30%

Financials

2025 2026
Net sales 1.34 1.19 1.11 1.01 1.9 126.54 1.93 13.31 5.21 66.02 5.01 4.91 211.27 1.02 0.91 0.84 0.77 1.44 96.23 1.47 10.12 3.96 50.21 3.81 3.73 160.66
Net income -22.58M -20.16M -18.73M -17.04M -32.06M -2.14B -32.64M -225M -88.05M -1.12B -84.75M -82.95M -3.57B -23.82M -21.26M -19.76M -17.98M -33.82M -2.26B -34.43M -237M -92.88M -1.18B -89.39M -87.5M -3.77B
Net Debt 13.44M 11.99M 11.15M 10.14M 19.08M 1.27B 19.42M 134M 52.39M 664M 50.43M 49.36M 2.12B 27.11M 24.2M 22.49M 20.46M 38.49M 2.57B 39.18M 270M 106M 1.34B 102M 99.58M 4.29B
Logo Pluristem Therapeutics
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
Employees
-